Ultragenyx Pharmaceutical Announces $400M Sale Of Additional 25% Royalty Interest From Kyowa Kirin On Future Sales Of Crysvita In U.S., Canada To OMERS

Author: Benzinga Newsdesk | November 04, 2025 04:13pm

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the sale, for $400 million, of an additional 25% of the company's royalty interest from Kyowa Kirin Co., Ltd on the future sales of Crysvita® (burosumab) in the United States (U.S.) and Canada to OMERS, one of Canada's largest defined benefit pension plans. OMERS will receive the additional 25% royalty interest on net sales of Crysvita® beginning in January 2028. Pursuant to the new agreement, OMERS will also continue to receive 30% of Crysvita® net sales in the U.S. and Canada following the achievement of the 2022 royalty purchase agreement transaction's cap of 1.45 times the purchase price. Total payments to OMERS pursuant to the new agreement are capped at 1.55 times the purchase price.

Posted In: RARE